Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia

The application of nucleoside analogue-based chemotherapy and immunotherapy with rituximab or alemtuzumab has increased both response rate and survival in patients with Chronic Lymphocytic Leukemia (CLL). However, because none of these therapies is curative, sequential therapeutic regimens are requi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortelezzi, Agostino, Sciumè, Mariarita, Reda, Gianluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407617/
https://www.ncbi.nlm.nih.gov/pubmed/22851972
http://dx.doi.org/10.1155/2012/393864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407617/
https://www.ncbi.nlm.nih.gov/pubmed/22851972
http://dx.doi.org/10.1155/2012/393864

Ejemplares similares